Correlation of Immunohistochemical Expression of MDR1, MRP1, Topoisomerase IIalpha with Prognostic Factors and Histoculture Drug Response Assay (HDRA) Result in Breast Carcinoma

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Korean Breast Cancer Society

• Publication date

  2004-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.4048/JKBCS.2004.7.4.228
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer.

  2004cited by this paper
• Serial Topoisomerase II Expression in Primary Breast Cancer and Response to Neoadjuvant Anthracycline-Based Chemotherapy

  2004cited by this paper
• Investigation of MRP‐1 protein and MDR‐1 P‐glycoprotein expression in invasive breast cancer: A prognostic study

  2004influential reference
• Nuclear expression of Y‐box‐binding protein‐1 correlates with P‐glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma

  2003cited by this paper
• ATP binding cassette transporters and drug resistance in breast cancer.

  2003influential reference
• Expression of Topoisomerase II-α and c-erbB-2 in Breast Cancer

  2002cited by this paper
• Y‐box factor YB‐1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI‐1

  2002cited by this paper
• The Reliability of Histoculture Drug Response Assay (HDRA) in Chemosensitivity Tests for Breast Cancer.

  2001cited by this paper
• Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.

  2001cited by this paper
• Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies.

  2000cited by this paper
• Expression of the multidrug resistance protein (MRP1) in breast cancer.

  1999influential reference
• Expression of drug resistance proteins in breast cancer, in relation to chemotherapy

  1997influential reference
• Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance.

  1997influential reference
• Multidrug resistance protein in recurrent breast cancer.

  1997influential reference
• The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer.

  1997cited by this paper
• Sequential assessment of multidrug resistance phenotype and measurement of S‐phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy

  1996cited by this paper
• DNA topoisomerases and topoisomerase inhibitors.

  1994cited by this paper
• The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump.

  1994cited by this paper
• P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors.

  1994influential reference
• Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer.

  1994cited by this paper
• In vitro assays for chemotherapy sensitivity.

  1993influential reference
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women

  1992cited by this paper
• Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line.

  1992cited by this paper
• Multidrug resistance from the clinical point of view.

  1991cited by this paper
• Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma.

  1991cited by this paper
• Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine.

  1991cited by this paper
• Expression of mdr1 and gst-pi in human breast tumours: comparison to in vitro chemosensitivity.

  1990cited by this paper

• Correlation of Early Systemic Recurrence with In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay in Stage II and III Breast Cancer Patients Treated with Doxorubicin-Based Chemotherapy

  2011cites this paper